Evidence map›Paper›PMID 33746047›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2021

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

P Grivas, A R Khaki, T M Wise-Draper, B French, C Hennessy, C-Y Hsu, Y Shyr, X Li, T K Choueiri, C A Painter and 118 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04354701 (The COVID-19 and Cancer Consortium), which is not on this map. Cited by 210 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 3 pooled it
26.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04354701 active not recruitingnot on this map

The COVID-19 and Cancer Consortium (CCC19) Registry

Typeobservational_patient_registrySponsorVanderbilt-Ingram Cancer CenterRan2020 to 2029Enrolled19,275ConditionsCOVID-19, Invasive Malignancy (Any Type)ArmsWeb-based REDCap survey
3 · Its place in the literature

Who cites it

210 citing papers in PubMed, 3 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Review
  10. Article
  11. Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Observational
  19. Article
  20. Article

150 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

128 authors at 20 institutions in 3 countries.

P GrivasUniversity of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA. Electronic address: pgrivas@uw.edu.
A R KhakiUniversity of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA; Stanford University, Stanford, USA.
T M Wise-DraperUniversity of Cincinnati Cancer Center, Cincinnati, USA.
B FrenchVanderbilt University Medical Center, Nashville, USA.
C HennessyVanderbilt University Medical Center, Nashville, USA.
C-Y HsuVanderbilt University Medical Center, Nashville, USA.
Y ShyrVanderbilt University Medical Center, Nashville, USA.
X LiVanderbilt University School of Medicine, Nashville, USA.
T K ChoueiriDana-Farber Cancer Institute, Boston, USA.
C A PainterBroad Institute, Cancer Program, Cambridge, USA.
S PetersLausanne University, Lausanne, Switzerland.
B I RiniVanderbilt University Medical Center, Nashville, USA.
M A ThompsonAdvocate Aurora Health, Milwaukee, USA.
S MishraVanderbilt University Medical Center, Nashville, USA.
D R RiveraDivision of Cancer Control and Population Sciences, National Cancer Institute, Rockville, USA.
J D AcobaUniversity of Hawaii Cancer Center, Honolulu, USA.
M Z AbidiUniversity of Colorado School of Medicine, Aurora, USA.
Z BakounyDana-Farber Cancer Institute, Boston, USA.
B BashirSidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
T Bekaii-SaabMayo Clinic Cancer Center, Phoenix, USA.
S BergCardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, USA.
E H BernickerHouston Methodist Cancer Center, Houston, USA.
M A BilenWinship Cancer Institute of Emory University, Atlanta, USA.
P BindalBeth Israel Deaconess Medical Center, Boston, USA.
R BishnoiUniversity of Florida, Gainesville, USA.
N BouganimMcGill University Health Centre, Montréal, Canada.
D W BowlesUniversity of Colorado School of Medicine, Aurora, USA.
A CabalUniversity of California San Diego, Moores Cancer Center, La Jolla, USA.
P F CaimiUniversity Hospitals Seidman Cancer Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA.
D D ChismThompson Cancer Survival Center, Knoxville, USA.
J CrowellSt. Elizabeth Healthcare, Edgewood, USA.
C CurranDana-Farber Cancer Institute, Boston, USA.
A DesaiMayo Clinic Cancer Center, Rochester, USA.
B DixonSt. Elizabeth Healthcare, Edgewood, USA.
D B DoroshowTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
E B DurbinMarkey Cancer Center, University of Kentucky, Lexington, USA.
A ElkriefMcGill University Health Centre, Montréal, Canada.
D FarmakiotisThe Warren Alpert Medical School of Brown University, Providence, USA.
A FazioTufts Medical Center Cancer Center, Boston and Stoneham, USA.
L A FecherUniversity of Michigan Rogel Cancer Center, Ann Arbor, USA.
D B FloraSt. Elizabeth Healthcare, Edgewood, USA.
C R FrieseUniversity of Michigan Rogel Cancer Center, Ann Arbor, USA.
J FuTufts Medical Center Cancer Center, Boston and Stoneham, USA.
S M GadgeelHenry Ford Cancer Institute/Henry Ford Health System, Detroit, USA.
M D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
D M GillIntermountain Healthcare, Salt Lake City, USA.
M J GloverStanford University, Stanford, USA.
S GoyalGeorge Washington University, Washington DC, USA.
P GroverUniversity of Cincinnati Cancer Center, Cincinnati, USA.
S GulatiUniversity of Cincinnati Cancer Center, Cincinnati, USA.
S GuptaCleveland Clinic Taussig Cancer Institute, Cleveland, USA.
S HalabiDuke University, Durham, USA.
T R HalfdanarsonMayo Clinic Cancer Center, Rochester, USA.
B HalmosAlbert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA.
D J HausrathVanderbilt University School of Medicine, Nashville, USA.
J E HawleyHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA.
E HsuHartford HealthCare, Hartford, USA; University of Connecticut, Farmington, USA.
M Huynh-LeGeorge Washington University, Washington DC, USA.
C HwangHenry Ford Cancer Institute/Henry Ford Health System, Detroit, USA.
C JaniMount Auburn Hospital, Cambridge, USA.
A JayarajHartford HealthCare, Hartford, USA.
D B JohnsonVanderbilt University Medical Center, Nashville, USA.
A KasiUniversity of Kansas Medical Center, Kansas City, USA.
H KhanThe Warren Alpert Medical School of Brown University, Providence, USA.
V S KoshkinUniversity of California, San Francisco, San Francisco, USA.
N M KudererAdvanced Cancer Research Group, LLC, Kirkland, USA.
D H KwonUniversity of California, San Francisco, San Francisco, USA.
P E LammersBaptist Cancer Center, Memphis, USA.
A LiBaylor College of Medicine, Houston, USA.
A Loaiza-BonillaCancer Treatment Centers of America, Philadelphia, USA.
C A LowIntermountain Healthcare, Salt Lake City, USA.
M B LustbergThe Ohio State University, Columbus, USA.
G H LymanUniversity of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
R R McKayUniversity of California San Diego, Moores Cancer Center, La Jolla, USA.
C McNairSidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
H MenonPenn State Health/Penn State Cancer Institute/St. Joseph Cancer Center, Hershey, USA.
R A MesaMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA.
V MicoSidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.
D MundtAdvocate Aurora Health, Milwaukee, USA.
G NagarajLoma Linda University Cancer Center, Loma Linda, USA.
E S NakasoneUniversity of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
J NakayamaCase Western Reserve University, Cleveland, USA; University Hospitals Cleveland Medical Center, Cleveland, USA.
A NizamCleveland Clinic Taussig Cancer Institute, Cleveland, USA.
N L NockUniversity Hospitals Seidman Cancer Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA.
C ParkUniversity of Cincinnati Cancer Center, Cincinnati, USA.
J M PatelBeth Israel Deaconess Medical Center, Boston, USA.
K G PatelUniversity of California Davis Comprehensive Cancer Center, Sacramento, USA.
P PeddiWillis-Knighton Cancer Center, Shreveport, USA.
N A PennellCleveland Clinic Taussig Cancer Institute, Cleveland, USA.
A J Piper-VallilloBeth Israel Deaconess Medical Center, Boston, USA.
M PucVirtua Health, Marlton, USA.
D RavindranathanWinship Cancer Institute of Emory University, Atlanta, USA.
M E ReevesLoma Linda University Cancer Center, Loma Linda, USA.
D Y ReubenMedical University of South Carolina, Charleston, USA.
L RosensteinGunderson Health System, La Crosse, USA.
R P RosovskyMassachusetts General Hospital, Harvard Medical School, Boston, USA.
S M RubinsteinUniversity of North Carolina, Chapel Hill, USA.
M SalazarMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA.
A L SchmidtDana-Farber Cancer Institute, Boston, USA.
G K SchwartzHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA.
M R ShahRutgers Cancer Institute of New Jersey, New Brunswick, USA.
S A ShahStanford University, Stanford, USA.
C ShahUniversity of Florida, Gainesville, USA.
J A ShayaUniversity of California San Diego, Moores Cancer Center, La Jolla, USA.
S R K SinghHenry Ford Cancer Institute/Henry Ford Health System, Detroit, USA.
M SmitsThedaCare Regional Cancer Center, Appleton, USA.
K E Stockerl-GoldsteinSiteman Cancer Center, Washington University School of Medicine, St. Louis, USA.
D G StoverThe Ohio State University, Columbus, USA.
M StreckfussAdvocate Aurora Health, Milwaukee, USA.
S SubbiahStanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, USA.
L TachikiUniversity of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, USA.
E TadesseAdvocate Aurora Health, Milwaukee, USA.
A ThakkarAlbert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA.
M D TuckerVanderbilt University Medical Center, Nashville, USA.
A K VermaAlbert Einstein Cancer Center/Montefiore Medical Center, Bronx, USA.
D C VinhMcGill University Health Centre, Montréal, Canada.
M WeissThedaCare Regional Cancer Center, Appleton, USA.
J T WuStanford University, Stanford, USA.
E Wulff-BurchfieldMount Auburn Hospital, Cambridge, USA.
Z XieMayo Clinic Cancer Center, Rochester, USA.
P P YuHartford HealthCare, Hartford, USA.
T ZhangDuke University, Durham, USA.
A Y ZhouSiteman Cancer Center, Washington University School of Medicine, St. Louis, USA.
H ZhuDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
L ZubiriMassachusetts General Hospital, Harvard Medical School, Boston, USA.
D P ShahMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA.
J L WarnerVanderbilt University Medical Center, Nashville, USA.
GdL LopesUniversity of Miami/Sylvester Comprehensive Cancer Center, Miami, USA.
Vanderbilt University Medical Center · USAurora Health Care · USDana-Farber Cancer Institute · USUniversity of Cincinnati · USBeth Israel Deaconess Medical Center · USCleveland Clinic · USHenry Ford Health System · USIcahn School of Medicine at Mount Sinai · USMayo Clinic · USMcGill University Health Centre · CAStanford University · USSt. Elizabeth Healthcare · USUniversity of California, San Diego · USBrown University · USCase Western Reserve University · USColumbia University Irving Medical Center · USDuke University · USEmory University · USFred Hutch Cancer Center · USGeorge Washington University · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001425NCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA013330NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA046592NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA054174NCI NIH HHS P30 CA056036NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA168524NCI NIH HHS P30 CA177558NCI NIH HHS P30 CA196521NCI NIH HHS P30 CA240139NCI NIH HHS T32 CA009515NCI NIH HHS T32 CA236621NCI NIH HHS U01 CA231840NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA190140
6 · The paper itself

Abstract

backgroundPatients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies. PATIENTS AND

methodsPatients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demographics, cancer status, anticancer therapy and timing, COVID-19-directed therapies, and laboratory measurements (among hospitalized patients).

resultsA total of 4966 patients were included (median age 66 years, 51% female, 50% non-Hispanic white); 2872 (58%) were hospitalized and 695 (14%) died; 61% had cancer that was present, diagnosed, or treated within the year prior to COVID-19 diagnosis. Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance status, recent cytotoxic chemotherapy, and hematologic malignancy were associated with higher COVID-19 severity. Among hospitalized patients, low or high absolute lymphocyte count; high absolute neutrophil count; low platelet count; abnormal creatinine; troponin; lactate dehydrogenase; and C-reactive protein were associated with higher COVID-19 severity. Patients diagnosed early in the COVID-19 pandemic (January-April 2020) had worse outcomes than those diagnosed later. Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, and DNA methyltransferase inhibitors) were associated with high 30-day all-cause mortality.

conclusionsClinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further studies are needed, caution may be required in utilizing particular anticancer therapies. CLINICAL TRIAL IDENTIFIER: NCT04354701.

Indexed as

COVID-19NeoplasmsAgedCOVID-19 TestingFemaleHumansMalePandemicsSARS-CoV-2anticancer therapycancerlaboratory measurementsneoplasmoutcomesSARS-CoV2

Identifiers

PMID33746047
PMCPMC7972830
OpenAlexW3136076419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.